Abstract Number: 2561 • 2013 ACR/ARHP Annual Meeting
Multiplex Cytokine Analysis Of Dermal Interstitial Blister Fluid In Systemic Sclerosis Defines Potential Pathogenic Pathways and Differentiates Clinical Subsets
Background/Purpose: Clinical diversity in systemic sclerosis (SSc) is likely to reflect multifaceted pathogenesis and the effect of key growth factors or cytokines operating within a…Abstract Number: 2563 • 2013 ACR/ARHP Annual Meeting
Modulating Myofibroblast Transition Of Human Scleroderma Fibroblasts Through Inhibition Of Rho Guanine Nucleotidase-Regulated Gene Transcription
Background/Purpose: Systemic sclerosis (SSc) or scleroderma, like many fibrotic disorders, has no effective therapy. Deposition of collagen and excess extracellular matrix depends on the transition…Abstract Number: 2566 • 2013 ACR/ARHP Annual Meeting
Nilotinib Treatment Effect In The Skin As Measured By DNA Microarray In Patients With Diffuse Systemic Sclerosis
Background/Purpose: Gene expression profiling by DNA microarray is used to identify potential biomarkers in Systemic Sclerosis (SSc). Discrete gene expression signatures have been observed to…Abstract Number: 2568 • 2013 ACR/ARHP Annual Meeting
Involvement Of Collagen-Binding Heat Shock Protein 47 In The Scleroderma-Associated Fibrosis
Background/Purpose: Scleroderma or systemic sclerosis (SSc) is characterized by the fibrosis of skin and visceral organs, especially the uncontrolled fibrosis of multiple organs. Collagen is…Abstract Number: 2569 • 2013 ACR/ARHP Annual Meeting
Serum S100A4 Levels Correlate With Skin Fibrosis and Lung Involvement In Systemic Sclerosis
Background/Purpose: Our previous study demonstrated that S100A4 is overexpressed in scleroderma (SSc) skin, fibroblasts and preclinical models of SSc in a TGF-β dependent manner. Furthermore,…Abstract Number: 2570 • 2013 ACR/ARHP Annual Meeting
Tenofovir But Not Adefovir Prevents Liver and Skin Fibrosis In Two Models Of Adenosine-Mediated Injury
Background/Purpose: Acyclic nucleoside phosphonates are a key class of antivirals commonly used in the treatment of both DNA and retroviral infections. Adefovir and tenofovir are…Abstract Number: 2571 • 2013 ACR/ARHP Annual Meeting
Pigment Epithelium Derived Factor Secreted By Activated Fibroblasts Can Contribute To Impaired Angio and Vasculogenesis In Scleroderma
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disorder characterized by tissue fibrosis and vasculopathy. This latter comprises both neointima proliferation and defective angio and vasculogenesis.…Abstract Number: 2541 • 2013 ACR/ARHP Annual Meeting
Disease Activity Does Not Improve Significantly In One System and Worsen In Another System
Background/Purpose: Systemic Lupus Erythematous Disease Activity Index-2000 (SLEDAI-2K) is a global index that describes disease activity overall in 9 systems. The use of multiple measures…Abstract Number: 2532 • 2013 ACR/ARHP Annual Meeting
Changes In Quality Of Life In The First 5 Years Of Disease In The Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) Cohort
Background/Purpose: The Medical Outcome Survey Short Form 36 (SF-36) is one of the most widely used tools for measuring patient reported outcomes. In cross-sectional studies,…Abstract Number: 2533 • 2013 ACR/ARHP Annual Meeting
Delta Neutrophil Index As a Marker For Differential Diagnosis Between Flare and Infection In Febrile Systemic Lupus Erythematosus Patients
Background/Purpose: The immature granulocyte count has been reported to be a marker of infection and sepsis. The difference in leukocyte subfractions (delta neutrophil index, DNI),…Abstract Number: 2534 • 2013 ACR/ARHP Annual Meeting
Pregnancy Complications In Lupus: Retrospective Observational Analysis From a US Health Claims Database
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease most frequently affecting women of childbearing age. Women with SLE are known to be at…Abstract Number: 2535 • 2013 ACR/ARHP Annual Meeting
Rare Autoantibodies To Cellular Antigens In Systemic Lupus Erythematosous
Background/Purpose: a high number of antinuclear antibody specificities can be detected in Systemic Lupus Erythematosous (SLE). Some of them are related to a distinct clinical…Abstract Number: 2536 • 2013 ACR/ARHP Annual Meeting
Lupus Impact Tracker Is Responsive To Changes In Physician Assessed Disease Status By Systemic Lupus Erythematosus Responder Index
Background/Purpose: Lupus Impact Tracker (LIT) is a 10-item patient reported outcome tool to measure the impact of Systemic Lupus Erythematosus (SLE) or its treatment on…Abstract Number: 2537 • 2013 ACR/ARHP Annual Meeting
Inactive Systemic Lupus Erythematosus: Cytokines and Soluble Tumor Necrosis Factor Receptors Response To Moderate/Intense Exercise
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterized by a chronic inflammation associated with worse cardiovascular outcome. Although a few studies have…Abstract Number: 2538 • 2013 ACR/ARHP Annual Meeting
Impact Of Omega-3 Fatty Acids On Quality Of Life In Systemic Lupus Erythematosus
Background/Purpose: A comprehensive metabolomic screen of sera from patients with Systemic Lupus Erythematosus (SLE) has shown that the concentrations of many substrates for energy generation,…
ACR Meeting Abstracts